E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion

被引：0
|
作者：
Hilary Glen
Susan Mason
Hitesh Patel
Kenneth Macleod
Valerie G Brunton
机构：
[1] Beatson Institute for Cancer Research,Edinburgh Cancer Research Centre
[2] University of Edinburgh,undefined
来源：
BMC Cancer | / 11卷
关键词：
Fibroblast Growth Factor Receptor; Wound Healing Assay; Platelet Derive Growth Factor Receptor; U2OS Cell; Lymphatic Vessel Density;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Multi-targeted tyrosine kinase inhibitor sunitinib: a novel strategy for sporadic malignant pheochromocytoma
    Sun Fu-kang
    He Hong-chao
    Su Ting-wei
    Zhou Wen-long
    Huang Xin
    Dai Jun
    Shen Zhou-jun
    [J]. CHINESE MEDICAL JOURNAL, 2012, 125 (12) : 2231 - 2234
  • [32] Linifanib - a multi-targeted receptor tyrosine kinase inhibitor and a low molecular weight gelator
    Marlow, Maria
    Al-Ameedee, Mohammed
    Smith, Thomas
    Wheeler, Simon
    Stocks, Michael J.
    [J]. CHEMICAL COMMUNICATIONS, 2015, 51 (29) : 6384 - 6387
  • [33] Multi-targeted tyrosine kinase inhibitor reverses resistance to immunotherapy in hepatic sarcomatoid carcinoma
    Chen, Juan
    Chen, Wenjuan
    Qu, Xiujuan
    Chen, Ying
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (20) : 17837 - 17848
  • [34] ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside
    Jianbiao Zhou
    Boon-Cher Goh
    Daniel H Albert
    Chien-Shing Chen
    [J]. Journal of Hematology & Oncology, 2
  • [35] TKI258, a novel, multi-targeted tyrosine kinase inhibitor for the treatment of breast cancer
    Liu, Hongyu
    Dieing, Annette
    Lehenbauer-Dehm, Sylvia
    Kuehnhardt, Dagmar
    Regierer, Anne
    Schulz, Carsten
    Storek, Benjamin
    Schwarck, Sandra
    Possinger, Kurt
    Eucker, Jan
    [J]. CANCER RESEARCH, 2009, 69
  • [36] ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside
    Zhou, Jianbiao
    Goh, Boon-Cher
    Albert, Daniel H.
    Chen, Chien-Shing
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2009, 2
  • [37] Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts
    Bruheim, Skjalg
    Kristian, Alexandr
    Uenaka, Toshimitsu
    Suo, Zhenhe
    Tsuruoka, Akihiko
    Nesland, Jahn M.
    Fodstad, Oystein
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2011, 129 (03) : 742 - 750
  • [38] Phase I dose-escalation study of E7080, a selective tyrosine kinase inhibitor, administered orally to patients with solid tumors.
    Hong, D. S.
    Koetz, B. S.
    Kurzrock, R.
    Senzer, N. N.
    Hanekom, W.
    Naing, A.
    Wheler, J. J.
    Mink, J.
    Ren, M.
    Nemunaitis, J. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [39] Mechanism of antitumor activity of E7080, a selective VEGFR and FGFR tyrosine kinase inhibitor (TKI), in combination with selective mutant BRAF inhibition.
    Matsui, J.
    Narita, Y.
    Semba, T.
    Adachi, Y.
    Kadowaki, T.
    Oestreicher, J.
    Matijevic, M.
    Byrne, M.
    Funahashi, Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [40] Sulfatinib, a novel multi-targeted tyrosine kinase inhibitor of FGFR1, CSF1R, and VEGFR1-3, suppresses osteosarcoma proliferation and invasion via dual role in tumor cells and tumor microenvironment
    Liao, Song
    Li, Jianxiong
    Gao, Song
    Han, Yuchen
    Han, Xinli
    Wu, Yanan
    Bi, Jingyou
    Xu, Meng
    Bi, Wenzhi
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
12345